The stock of Cellectar Biosciences Inc (NASDAQ: CLRB) has increased by 5.73 when compared to last closing price of 0.31.Despite this, the company has seen a gain of 15.31% in its stock price over the last five trading days. globenewswire.com reported 2025-02-05 that FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows:
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
Additionally, the 36-month beta value for CLRB is 1.01. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLRB is 45.22M and currently, short sellers hold a 5.21% ratio of that float. The average trading volume of CLRB on February 19, 2025 was 2.82M shares.
CLRB’s Market Performance
CLRB stock saw an increase of 15.31% in the past week, with a monthly gain of 36.39% and a quarterly increase of -83.48%. The volatility ratio for the week is 9.13%, and the volatility levels for the last 30 days are 8.54% for Cellectar Biosciences Inc (CLRB). The simple moving average for the past 20 days is 21.01% for CLRB’s stock, with a -82.12% simple moving average for the past 200 days.
Analysts’ Opinion of CLRB
Many brokerage firms have already submitted their reports for CLRB stocks, with Ladenburg Thalmann repeating the rating for CLRB by listing it as a “Buy.” The predicted price for CLRB in the upcoming period, according to Ladenburg Thalmann is $13 based on the research report published on December 05, 2024 of the previous year 2024.
ROTH Capital gave a rating of “Buy” to CLRB, setting the target price at $10 in the report published on January 21st of the previous year.
CLRB Trading at -8.62% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.54% of loss for the given period.
Volatility was left at 8.54%, however, over the last 30 days, the volatility rate increased by 9.13%, as shares surge +28.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -78.23% lower at present.
During the last 5 trading sessions, CLRB rose by +11.11%, which changed the moving average for the period of 200-days by -89.87% in comparison to the 20-day moving average, which settled at $0.2738. In addition, Cellectar Biosciences Inc saw 11.07% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CLRB
Current profitability levels for the company are sitting at:
- -156.13 for the present operating margin
- 0.32 for the gross margin
The net margin for Cellectar Biosciences Inc stands at -135.05. The total capital return value is set at -3.04. Equity return is now at value -474.63, with -170.31 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -90.23. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -415.86.
Currently, EBITDA for the company is -38.77 million with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of -56.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In conclusion, Cellectar Biosciences Inc (CLRB) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
